LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "dopamine agonists" as a keyword



DRD4 gene polymorphism and impulse control disorder induced by dopamine agonists in Parkinson's disease

Sign Up to like & get
recommendations! Published in 2024 at "Annals of Clinical and Translational Neurology"

DOI: 10.1002/acn3.52111

Abstract: Impulse control disorders and their consequences display variability among individuals, indicating potential involvement of environmental and genetic factors. In this retrospective study, we analyzed a cohort of Parkinson's disease patients treated with dopamine agonists and… read more here.

Keywords: impulse control; dopamine agonists; parkinson disease; gene polymorphism ... See more keywords

Dopamine Agonists and Risk of Lung Cancer in Patients with Restless Legs Syndrome.

Sign Up to like & get
recommendations! Published in 2023 at "Pharmacoepidemiology and drug safety"

DOI: 10.1002/pds.5596

Abstract: To examine the association between long‐term use of dopamine agonists (DAs) and the risk of lung cancer in patients with restless legs syndrome (RLS). read more here.

Keywords: lung cancer; patients restless; cancer patients; restless legs ... See more keywords

The Role of Dopamine Agonists in Pituitary Adenomas.

Sign Up to like & get
recommendations! Published in 2020 at "Endocrinology and metabolism clinics of North America"

DOI: 10.1016/j.ecl.2020.05.006

Abstract: Dopamine agonist therapy is the primary therapy for prolactin-secreting adenomas and usually results in normoprolactinemia, eugonadism, and tumor reduction. Cabergoline is superior to bromocriptine with regard to efficacy and tolerance. Withdrawal of cabergoline can be… read more here.

Keywords: dopamine agonists; agonists pituitary; pituitary adenomas; cabergoline ... See more keywords
Photo from wikipedia

Hyperprolactinemia after menopause: Diagnosis and management.

Sign Up to like & get
recommendations! Published in 2021 at "Maturitas"

DOI: 10.1016/j.maturitas.2021.06.014

Abstract: Most prolactinomas are diagnosed in women of reproductive age and are generally microadenomas. Prolactinomas diagnosed in postmenopausal women are less common and are not usually associated with the typical syndrome induced by prolactin excess, including… read more here.

Keywords: dopamine agonists; management; menopause diagnosis; hyperprolactinemia menopause ... See more keywords
Photo from wikipedia

The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists

Sign Up to like & get
recommendations! Published in 2020 at "Molecular and Cellular Endocrinology"

DOI: 10.1016/j.mce.2020.111033

Abstract: Dopamine agonists (DAs), such as cabergoline and bromocriptine, are the first-line clinical treatment for prolactinomas. Our previous study demonstrated that long noncoding RNA H19 expression is frequently downregulated in human primary pituitary adenomas and is… read more here.

Keywords: long noncoding; dopamine agonists; expression; treatment prolactinomas ... See more keywords
Photo from academic.microsoft.com

Use of dopamine agonists to target angiogenesis in women with endometriosis.

Sign Up to like & get
recommendations! Published in 2020 at "Human reproduction"

DOI: 10.1093/humrep/deaa337

Abstract: Endometriosis requires medical management during a woman's reproductive years. Most treatments aim to create a hypoestrogenic milieu, but for patients wishing to conceive, drugs that allow normal ovarian function are needed. Targeting angiogenesis, a hallmark… read more here.

Keywords: use dopamine; endometriosis; dopamine agonists; women endometriosis ... See more keywords

Dopamine agonists for the treatment of pituitary tumours: From ergot extracts to next generation therapies

Sign Up to like & get
recommendations! Published in 2023 at "British Journal of Clinical Pharmacology"

DOI: 10.1111/bcp.15660

Abstract: Dopamine agonists are a key tool in the therapeutic arsenal of endocrinologists worldwide. They exert their effects by binding to dopamine‐2 (D2) receptors expressed by pituitary tumour cells to modulate hormonal secretion and tumour size.… read more here.

Keywords: treatment pituitary; next generation; pituitary tumours; treatment ... See more keywords

Chronic dizziness in restless legs syndrome (RLS) patients responsive to levodopa or dopamine agonists

Sign Up to like & get
recommendations! Published in 2024 at "BMJ Case Reports"

DOI: 10.1136/bcr-2023-255700

Abstract: Apart from the legs, restless legs syndrome (RLS) also affects the arms, head, neck, face, oral cavity, genital area, abdomen, intestines and bladder. RLS is also linked to several comorbid diseases, including headache disorders. Its… read more here.

Keywords: chronic dizziness; history; dizziness; levodopa dopamine ... See more keywords
Photo from wikipedia

Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors

Sign Up to like & get
recommendations! Published in 2021 at "Parkinson's Disease"

DOI: 10.1155/2021/9952743

Abstract: Objective To investigate the use of dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors in the Norwegian population, between 1 July 2006 and 31 December 2016. Our primary endpoint was time until need for… read more here.

Keywords: mao inhibitor; dopamine agonists; mao inhibitors; dopamine agonist ... See more keywords

Balancing Dopamine: Managing Parkinson’s Disease and Psychiatric Symptoms through Agonist-Antagonist Pharmacotherapy

Sign Up to like & get
recommendations! Published in 2025 at "European Psychiatry"

DOI: 10.1192/j.eurpsy.2025.814

Abstract: Introduction Parkinson’s disease (PD) is characterized by basal ganglia dopamine depletion, leading to motor symptoms. Psychiatric symptoms, like psychosis, are associated with dopamine overactivity in the mesolimbic and mesocortical system. PD patients sometimes require both… read more here.

Keywords: dopamine; affinity; dopamine agonists; parkinson disease ... See more keywords

Advances in the Therapeutic Use of Non-ergot Dopamine Agonists in the Treatment of Motor and Non-motor Symptoms of Parkinson's Disease.

Sign Up to like & get
recommendations! Published in 2022 at "Current neuropharmacology"

DOI: 10.2174/1570159x20666220915091022

Abstract: Dopamine (DA) agonists, as an excellent dopamine replacement therapy for patients with early and advanced Parkinson's disease (PD), play a vital role in controlling motor and several non-motor symptoms. Besides, the application of DA agonists… read more here.

Keywords: motor symptoms; non motor; parkinson disease; non ergot ... See more keywords